Literature DB >> 11376559

Overexpression of latent transforming growth factor-beta 1 (TGF-beta 1) binding protein 1 (LTBP-1) in association with TGF-beta 1 in ovarian carcinoma.

T Higashi1, T Sasagawa, M Inoue, R Oka, L Shuangying, K Saijoh.   

Abstract

Using the differential display method, latent transforming growth factor-beta 1 (TGF-beta 1) binding protein 1 (LTBP-1) mRNA was identified as one of the enriched mRNAs in ovarian carcinoma tissues after isolation of genes responsible for the development of ovarian cancer. Semi-quantitative reverse transcription (RT)-PCR analysis showed that expression of LTBP-1 and TGF-beta 1 mRNAs was much higher in both serous and mucinous adenocarcinomas than in their benign counterparts, including serous and mucinous cystadenomas and cystadenomas of low malignant potential (LMPs). Immunohistochemical analysis demonstrated that only proliferating benign adenoma cells were immunoreactive for both LTBP-1 and TGF-beta 1 proteins. In contrast, most serous and mucinous adenocarcinoma cells and their surrounding stroma were intensely immunoreactive for LTBP-1 and TGF-beta 1. LTBP-1 and TGF-beta 1 proteins, and their complex forms were identified in ovarian carcinoma cell lines and in their culture media by western blot analysis, suggesting these products were produced in ovarian carcinoma cells. RT-PCR analysis demonstrated that LTBP-1L, one of the LTBP-1 transcripts that has a strong activity in targeting the latent form of TGF-beta 1 to extracellular matrix (ECM), was predominantly expressed in ovarian carcinomas. Taken together, the results suggest that upregulation of LTBP-1 in ovarian carcinoma cells may have an important role in distributing TGF-beta1 in the stromal tissues surrounding carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11376559      PMCID: PMC5926747          DOI: 10.1111/j.1349-7006.2001.tb01123.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  32 in total

1.  Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma.

Authors:  N Ito; S Kawata; S Tamura; K Takaishi; Y Shirai; S Kiso; I Yabuuchi; Y Matsuda; M Nishioka; S Tarui
Journal:  Cancer Res       Date:  1991-08-01       Impact factor: 12.701

2.  Expression of a dominant-negative mutant TGF-beta type II receptor in transgenic mice reveals essential roles for TGF-beta in regulation of growth and differentiation in the exocrine pancreas.

Authors:  E P Böttinger; J L Jakubczak; I S Roberts; M Mumy; P Hemmati; K Bagnall; G Merlino; L M Wakefield
Journal:  EMBO J       Date:  1997-05-15       Impact factor: 11.598

3.  Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential.

Authors:  D R Welch; A Fabra; M Nakajima
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

4.  A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance.

Authors:  G Torre-Amione; R D Beauchamp; H Koeppen; B H Park; H Schreiber; H L Moses; D A Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

Review 5.  TGF-beta signalling from cell membrane to nucleus through SMAD proteins.

Authors:  C H Heldin; K Miyazono; P ten Dijke
Journal:  Nature       Date:  1997-12-04       Impact factor: 49.962

6.  Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors.

Authors:  R Derynck; D V Goeddel; A Ullrich; J U Gutterman; R D Williams; T S Bringman; W H Berger
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

7.  Efficient association of an amino-terminally extended form of human latent transforming growth factor-beta binding protein with the extracellular matrix.

Authors:  A Olofsson; H Ichijo; A Morén; P ten Dijke; K Miyazono; C H Heldin
Journal:  J Biol Chem       Date:  1995-12-29       Impact factor: 5.157

8.  Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells.

Authors:  M Urashima; A Ogata; D Chauhan; M Hatziyanni; M B Vidriales; D A Dedera; R L Schlossman; K C Anderson
Journal:  Blood       Date:  1996-03-01       Impact factor: 22.113

9.  Differential expression of nitric oxide synthase isoforms in form-deprived chick eyes.

Authors:  S Fujii; S Honda; Y Sekiya; M Yamasaki; M Yamamoto; K Saijoh
Journal:  Curr Eye Res       Date:  1998-06       Impact factor: 2.424

10.  Extracellular fibrillar structure of latent TGF beta binding protein-1: role in TGF beta-dependent endothelial-mesenchymal transformation during endocardial cushion tissue formation in mouse embryonic heart.

Authors:  Y Nakajima; K Miyazono; M Kato; M Takase; T Yamagishi; H Nakamura
Journal:  J Cell Biol       Date:  1997-01-13       Impact factor: 10.539

View more
  10 in total

1.  Novel functional single nucleotide polymorphisms in the latent transforming growth factor-beta binding protein-1L promoter: effect on latent transforming growth factor-beta binding protein-1L expression level and possible prognostic significance in ovarian cancer.

Authors:  Tomomi Higashi; Satoru Kyo; Masaki Inoue; Hideji Tanii; Kiyofumi Saijoh
Journal:  J Mol Diagn       Date:  2006-07       Impact factor: 5.568

2.  LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.

Authors:  Yuxiu Gao; Ning Shan; Cheng Zhao; Yunhai Wang; Fuliang Xu; Jiacun Li; Xiaoqian Yu; Lifeng Gao; Zhengjun Yi
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition.

Authors:  Thuy-Vy Do; Lena A Kubba; Hongyan Du; Charles D Sturgis; Teresa K Woodruff
Journal:  Mol Cancer Res       Date:  2008-05       Impact factor: 5.852

4.  Latent transforming growth factor-beta binding protein-1 in circulating plasma as a novel biomarker for early detection of hepatocellular carcinoma.

Authors:  Bangrong Cao; Lei Yang; Weiqi Rong; Lin Feng; Naijun Han; Kaitai Zhang; Shujun Cheng; Jianxiong Wu; Ting Xiao; Yanning Gao
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

Review 5.  The role of the tumor stroma in ovarian cancer.

Authors:  Ben Davidson; Claes G Trope; Reuven Reich
Journal:  Front Oncol       Date:  2014-05-13       Impact factor: 6.244

6.  Disruption of LTBP4 Inhibition-Induced TGFβ1 Activation Promoted Cell Proliferation and Metastasis in Skin Melanoma by Inhibiting the Activation of the Hippo-YAP1 Signaling Pathway.

Authors:  Lina Wang; Dongrun Tang; Tong Wu; Fengyuan Sun
Journal:  Front Cell Dev Biol       Date:  2022-02-17

7.  Expression and regulation of latent TGF-beta binding protein-1 transcripts and their splice variants in human glomerular endothelial cells.

Authors:  Joon Hyeok Kwak; Ji Su Woo; Kunyoo Shin; Hee Joon Kim; Hoe Su Jeong; Dong Cheol Han; Sung Il Kim; Choon Sik Park
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

8.  Differential expression profiling of head and neck squamous cell carcinoma (HNSCC).

Authors:  F Lemaire; R Millon; J Young; A Cromer; C Wasylyk; I Schultz; D Muller; P Marchal; C Zhao; D Melle; L Bracco; J Abecassis; B Wasylyk
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

Review 9.  Epithelial-to-Mesenchymal Transition in the Female Reproductive Tract: From Normal Functioning to Disease Pathology.

Authors:  Olena Bilyk; Mackenzie Coatham; Michael Jewer; Lynne-Marie Postovit
Journal:  Front Oncol       Date:  2017-07-05       Impact factor: 6.244

10.  CD109 regulates in vivo tumor invasion in lung adenocarcinoma through TGF-β signaling.

Authors:  Tetsuro Taki; Yukihiro Shiraki; Atsushi Enomoto; Liang Weng; Chen Chen; Naoya Asai; Yoshiki Murakumo; Kohei Yokoi; Masahide Takahashi; Shinji Mii
Journal:  Cancer Sci       Date:  2020-10-24       Impact factor: 6.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.